Federal Register on 10/25/2017 and available online at https://federalregister.gov/d/2017-23128, and on FDsys.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby

given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions

could disclose confidential trade secrets or commercial property such as patentable material, and

personal information concerning individuals associated with the grant applications, the

disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Multi-Site Studies for System-Level Implementation of Substance Use

Prevention and Treatment Services (R01; R34)

Date: November 7, 2017

Time: 1:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard

Rockville, MD 20852

(Telephone Conference Call)

1

Contact Person: Gerald L. McLaughlin, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Blvd., Room 4238, MSC 9550

Bethesda, MD 20892-9550

301-827-5819 gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Limited Competition - Cohort Studies of HIV/AIDS and Substance Abuse

(U01)

Date: November 7, 2017

Time: 2:00 PM to 3:30 PM

Agenda: To review and evaluate cooperative agreement applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Advancing Exceptional Research on HIV/AIDS and Substance Abuse

(R01)

Date: November 10, 2017

Time: 12:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Hiromi Ono, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS

6001 Executive Boulevard, Room 4238, MSC 9550

Bethesda, MD 20892

301-827-5820

hiromi.ono@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Wearable to Track Recovery and Relapse Factors for People w/Addiction

(R43, R44)

Date: November 21, 2017

Time: 1:00 PM to 4:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Julia Berzhanskaya, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4234, MSC 9550

Bethesda, MD 20892

301-827-5840

julia.berzhanskaya@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

NIDA Research Education Program for Clinical Researchers and

Clinicians (R25)

Date: December 4, 2017

Time: 12:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boule

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Blvd., Room 4238, MSC 9550

Bethesda, MD 20892-9550

301-827-5819 gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Nasal Delivery of CNS Therapeutics (R41, R42, R43, R44)

Date: December 5, 2017

Time: 1:00 PM to 4:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard

Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Julia Berzhanskaya, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4234, MSC 9550

Bethesda, MD 20892

301-827-5840

julia.berzhanskaya@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Conference Grant Review (R13)

Date: December 6, 2017

Time: 1:00 PM to 4:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center 6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Shang-Yi Anne Tsai, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

shangyi.tsai@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: October 19, 2017

\_\_\_\_\_

Natasha M. Copeland, Program Analyst

Office of Federal Advisory Committee Policy

[FR Doc. 2017-23128 Filed: 10/24/2017 8:45 am; Publication Date: 10/25/2017]